Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $29.33 Consensus Target Price from Analysts

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) has received a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $29.3333.

Several research firms have recently issued reports on CGEM. Wall Street Zen cut shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Guggenheim began coverage on Cullinan Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $30.00 target price on the stock. Wedbush lifted their target price on Cullinan Therapeutics from $25.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. Zacks Research lowered shares of Cullinan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Finally, Citigroup initiated coverage on Cullinan Therapeutics in a research note on Tuesday, February 17th. They set a “buy” rating and a $33.00 price objective for the company.

Cullinan Therapeutics News Roundup

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Analyst bullish thesis — A recent write-up upgrades Cullinan to a Buy, citing a deep T‑cell engager pipeline, strong management, long-lived IP and a cash position north of $430M that supports development. The note highlights CLN‑049 (FLT3xCD3) showing ~30% complete remission rates in AML, favorable safety, broad applicability and a plausible single‑arm accelerated approval path, all of which underpin upside expectations. Seeking Alpha: Thesis Strengthening For This T-Cell Engager Specialist
• Neutral Sentiment: Technical/fundamental context — The stock is trading above its 50‑day ($11.26) and 200‑day ($9.17) moving averages and remains well off its 52‑week low, reflecting recent positive momentum; market cap is roughly $827M. MarketBeat: CGEM profile
• Negative Sentiment: Insider sales — CEO Nadim Ahmed sold 16,381 shares (≈$223k) on Feb 20, trimming his stake ~3.9%. CEO Filing
• Negative Sentiment: Insider sales — CFO Mary Kay Fenton sold 4,398 shares (≈$59.9k) on Feb 20, reducing her position ~3.4%. CFO Filing
• Negative Sentiment: Insider sales — Other insiders (Jennifer Michaelson, Jacquelyn Sumer, Jeffrey A. Jones) sold on Feb 20 (combined ~20,466 shares, ≈$284k total), each trimming low-single‑digit percentages of their holdings. The simultaneity and size of these sales introduce short‑term selling pressure despite the bullish clinical narrative. Insider Filings (examples)

Cullinan Therapeutics Stock Performance

Shares of Cullinan Therapeutics stock opened at $13.99 on Thursday. Cullinan Therapeutics has a fifty-two week low of $5.68 and a fifty-two week high of $14.51. The company has a fifty day moving average of $11.33 and a 200 day moving average of $9.22. The company has a market capitalization of $826.53 million, a P/E ratio of -4.23 and a beta of -0.09.

Insider Activity

In other Cullinan Therapeutics news, CFO Mary Kay Fenton sold 4,398 shares of the stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $13.62, for a total value of $59,900.76. Following the completion of the sale, the chief financial officer directly owned 126,380 shares in the company, valued at approximately $1,721,295.60. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jacquelyn L. Sumer sold 3,742 shares of the company’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $13.62, for a total transaction of $50,966.04. Following the transaction, the insider owned 131,690 shares in the company, valued at approximately $1,793,617.80. This trade represents a 2.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 71,081 shares of company stock worth $879,045 over the last quarter. Company insiders own 6.07% of the company’s stock.

Institutional Trading of Cullinan Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CGEM. Caitong International Asset Management Co. Ltd lifted its position in Cullinan Therapeutics by 62.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock valued at $28,000 after purchasing an additional 1,036 shares during the period. CWM LLC increased its holdings in Cullinan Therapeutics by 51.5% in the 4th quarter. CWM LLC now owns 3,876 shares of the company’s stock worth $40,000 after acquiring an additional 1,318 shares in the last quarter. Signaturefd LLC raised its position in shares of Cullinan Therapeutics by 689.7% during the 4th quarter. Signaturefd LLC now owns 4,130 shares of the company’s stock worth $43,000 after purchasing an additional 3,607 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock valued at $62,000 after acquiring an additional 2,523 shares during the last quarter. Finally, Quarry LP acquired a new position in Cullinan Therapeutics in the 4th quarter valued at $99,000. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.